Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib? that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.

Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

Abstract: Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease.

Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.

Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Abstract: A system for dispensing a sample into a buffer liquid includes a pressure chamber having pressure supply means for generating an overpressure within the pressure chamber. An inlet capillary supplies a buffer liquid to an outlet end arranged in the pressure chamber, and an outlet capillary discharges the buffer liquid from the pressure chamber. The outlet capillary has an inlet end in the pressure chamber facing the outlet end of the inlet capillary to form a capillary gap. A dispenser having a dispensing end is in the pressure chamber at the capillary gap to allow the sample at the dispensing end to be dispensed into the buffer liquid entering the outlet capillary inlet end. The pressure chamber includes a sample port that allows the dispenser to be moved into and out of the pressure chamber.

Abstract: A robotic microplate storage system includes a freezer room having freezing units and a first robot for moving and removing microplates into and out of the freezing unit. The first robot can also transfer microplates to a processing station, where the microplates are stored in a microplate recipient within the freezing unit. The storage system may also include at least one processing room which is thermally separated from the freezer room. Each processing room may include a processing station having a tube transfer module and a second robot for moving the microplates between the microplate recipients and the tube transfer module. The first robot may be designed such that it is only capable of removing a microplate recipient from and moving it into a freezing unit as well as transferring it from a freezing unit to a processing station or vice versa.

Abstract: The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Abstract: The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: An automated analyzer and a reagent vessel opening/closing device allows reduction of the time period during which reagent vessels are opened unnecessarily. The reagent vessel opening/closing device opens or closes the lids of reagent vessels when the reagent vessels are at a dispensing/stirring position on a reagent vessel transfer device of an automated analyzer. The device for opening/closing the lids of reagent vessels includes a hook base secured to a unit base and a hook-base drive unit for moving the hook base with respect to the unit base in opening/closing directions of the lids of the reagent vessels. A plurality of hooks are attached to the hook base and a plurality of motors are each adapted to slide one of the hooks with respect to the hook base to engage/disengage the hook with/from the lid of a reagent vessel.

Abstract: The present invention provides methods and means for identifying a cancer-patient disposed to respond favourably to a therapeutic antibody as well as methods for in vivo selecting a xenograft tumor model which is most qualified for preclinical testing of a therapeutic antibody. These methods apply near-infrared fluorescence imaging which is an excellent imaging technology because of its simplicity, fast scanning times and non-hazardous radiation.

Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: A method of purifying a glycan and/or a glycoconjugate comprising the steps of: (a) providing a stationary phase that comprises cotton; (b) applying a glycan and/or glycoconjugate-containing sample to the stationary phase; (c) washing the stationary phase with a first solvent; and (d) eluting the glycan and/or glycoconjugate from the stationary phase with a second solvent. A kit for purifying a glycan and/or glycoconjugate, the kit comprising: a stationary phase comprising cotton; and instructions for purifying a glycan and/or glycoconjugate according to the disclosed method.

Abstract: A method for removing a fluid medium from a container. The method comprises providing a removal device with a closed-off, sterilizable interior, with a needle element being held in the interior, the interior being closed off by a perforable sealing element; providing the container which contains the fluid medium, the container having a container wall with a perforable section; connecting the removal device and the container, the perforable section and the perforable sealing element being interconnected such that a protected region is created between the perforable section and the perforable sealing element, the protected region being closed off with respect to the surroundings in a substantially germ-free fashion as a result of the connection; and perforating the perforable sealing element and the perforable section by means of the needle element, the needle element penetrating the protected region.

Abstract: An automated analyzer and a reagent vessel opening/closing device allows reduction of the time period during which reagent vessels are opened unnecessarily. The reagent vessel opening/closing device opens or closes the lids of reagent vessels when the reagent vessels are at a dispensing/stirring position on a reagent vessel transfer device of an automated analyzer. The device for opening/closing the lids of reagent vessels includes a hook base secured to a unit base and a hook-base drive unit for moving the hook base with respect to the unit base in opening/closing directions of the lids of the reagent vessels. A plurality of hooks are attached to the hook base and a plurality of motors are each adapted to slide one of the hooks with respect to the hook base to engage/disengage the hook with/from the lid of a reagent vessel.